Author:
De Bolòs Anna,Sureda-Gómez Marta,Carreras-Caballé Maria,Rodríguez Marta-Leonor,Clot Guillem,Beà Silvia,Giné Eva,Campo Elias,Balsas Patricia,Amador Virginia
Abstract
AbstractMantle cell lymphoma (MCL) is an incurable B-cell neoplasm characterized by an aggressive behavior, short responses to conventional therapies and SOX11 overexpression, which is associated with aggressive disease features and inferior clinical outcome of patients. Oxidative stress is known to induce tumorigenesis and tumor progression, whereas high expression levels of antioxidant genes have been associated with chemoresistance in different cancers. However, the role of oxidative stress in MCL pathogenesis and the involvement of SOX11 regulating redox homeostasis in MCL cells are largely unknown. Here, by integrating gene set enrichment analysis of two independent series of MCL, we observed that SOX11+ MCL had higher reactive oxygen species (ROS) levels compared to SOX11− MCL primary tumors and increased expression of Peredoxine2 (PRDX2), which upregulation significantly correlated with SOX11 overexpression, higher ROS production and worse overall survival of patients. SOX11 knockout (SOX11KO) significantly reduced PRDX2 expression, and SOX11KO and PRDX2 knockdown (PRDX2KD) had increased ROS levels and ROS-mediated tumor cell death upon treatment with drugs, compared to control MCL cell lines. Our results suggest an aberrant redox homeostasis associated with chemoresistance in aggressive MCL through SOX11-mediated PRDX2 upregulation, highlighting PRDX2 as promising target for new therapeutic strategies to overcome chemoresistance in aggressive MCLs.
Funder
Agència de Gestió d'Ajuts Universitaris i de Recerca
Ministerio de Ciencia, Innovación y Universidades
Fundación Científica Asociación Española Contra el Cáncer
La Fundació La Marató de TV3
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Swerdlow, S. H. et al. Mantle cell lymphoma. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edn (eds Swedlow, S. H., Campo, E., Harris, N. L. et al.) 285–290 (IARC Press, 2017).
2. Veloza L. R.-C. I. & Campo, E. Mantle cell lymphoma pathology update in the 2016 WHO classification. Ann. Lymphoma 3(3) (2019).
3. Beekman, R., Amador, V. & Campo, E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr. Opin. Hematol. 25(4), 299–306 (2018).
4. Navarro, A. et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 72(20), 5307–5316 (2012).
5. Vose, J. M. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 87(6), 604–609 (2012).